[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"dupuytren-contracture\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:dupuytren-contracture":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,47,78,98,128,166,195,221,246],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100643111","phase-1-safety-and-efficacy-study-of-collagenase-cnt201-injection-for-treatment-of-dupuytrens-contracture-100643111",false,"NCT07640425","Safety and Efficacy Study of Collagenase CNT201 Injection for Treatment of Dupuytren's Contracture","A Phase 1\u002F2, Multicenter, Dose Escalating, Dose Expanding, Adaptive Study to Assess Safety, Tolerability, Efficacy and Pharmacokinetics of Collagenase CNT201 in Adult Participants With Dupuytren's Contracture","Inclusion Criteria:\n\n* Men and women, 18 to 75 years of age, inclusive.\n* Participants with a diagnosis of DC, with a fixed flexion deformity of at least 1 finger, other than the thumb, that have a contracture at least 20°, but not greater than 100°, for MP (not greater than 80° for PIP) joints, caused by a palpable cord.\n* Participants who have a positive Table Top Test, defined as the inability to simultaneously place the affected finger(s) and palm flat against a tabletop.\n* Participants who are naive to CNT201 treatment.\n* Participants who are judged to be in good health, based upon the results of a medical history, physical examination, and safety laboratory profile.\n* Participants who are willing to voluntarily sign and date the Informed Consent Form (ICF) approved by the Institutional Review Board\u002FIndependent Ethics Committee (IRB\u002FIEC).\n\nExclusion Criteria:\n\n* Participants previously exposed to collagenase Clostridium histolyticum for treatment of Dupuytren's disease (Xiaflex, Xiapex®).\n* Participants who have received other treatments for advanced Dupuytren's disease, including surgery (fasciectomy or fasciotomy), needle aponeurotomy\u002Ffasciotomy, or injection of verapamil and\u002For interferon on the selected primary joint within 90 days before the first dose of study treatment.\n* Participants with a chronic muscular, neurological, or neuromuscular disorder that affects the hands, or other medical condition which in the Investigator's opinion will make the participant unsuitable for enrollment in the study.\n* Participants who have a known recent history of stroke, bleeding, a disease process that affected the hands, or other medical condition (eg, testing positive for tuberculosis \\[TB\\] or Coronavirus disease 2019 \\[COVID-19\\], etc), or history of alcoholism or drug abuse, which in the Investigator's opinion, would make the participant unsuitable for enrollment in the study.\n* Participants who have a known allergic response to collagenase or any other excipient of CNT201 or Xiaflex.\n* Participants who have received a doxycycline or tetracycline derivative within 14 days before the beginning of the study (tetracycline derivatives may inhibit the collagenolytic activity of mammalian collagenase homologs).\n* Participants who have received an anticoagulant (except aspirin ≤150 mg\u002Fday) within 7 days before the start of the study.\n* Female participants who are nursing or pregnant, or plan to become pregnant during the study treatment stage of the study.\n* Participants who have been treated with any investigational drug within 30 days of first dose of study treatment.","ALL","18 Years","75 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE1","PHASE2","This trial is a multicenter, Phase 1\u002F2, study to assess the safety, tolerability, efficacy, PK, and immunogenicity of CNT201 in adult participants with DC (Dupuytren's Contracture).",[28,29],"Dupuytren Contracture","Dupuytren Disease of Finger",[31,32,33],"collagenase injection","CCH","CNT201","RECRUITING","2026-06-10",{"date":37,"type":38},"2026-06-12","ACTUAL",{"date":40,"type":38},"2024-07-23",{"date":42,"type":21},"2027-07-25",{"name":44,"class":45},"CONNEXT","INDUSTRY",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":46},"100371894","post-contracture-release-radiation-for-dupuytrens-disease-100371894","NCT04122313","Post-contracture Release Radiation for Dupuytren's Disease","Efficacy of Post-contracture Release Radiation for the Treatment of Dupuytren's Disease","Inclusion Criteria:\n\n* Diagnoses of Dupuytren's disease\n* English-speaking\n\nExclusion Criteria:\n\n\\- Patients with Dupuytren's disease who are not currently seeking treatment",{"count":55,"type":21},50,"OBSERVATIONAL","To determine if the clinical impression of clinicians, ie that patients are improving with the current treatment pathway for Dupuytren's (contracture release followed by radiation), can be substantiated with scientific evidence.",[59,28,60,29,61,62,63,64,65,66,67],"Dupuytren's Disease","Dupuytren Disease of Palm and Finger","Dupuytrens Contracture of Both Hands","Dupuytren's Disease of Palm of Right Hand","Dupuytren's Disease of Palm of Left Hand","Dupuytren Contracture of Right Palm","Dupuytren Contracture of Left Palm","Dupuytren's Contracture Left","Dupuytren's Contracture Right","2026-03-16",{"date":70,"type":38},"2026-03-19",{"date":72,"type":38},"2019-05-31",{"date":74,"type":21},"2029-03-01",{"name":76,"class":77},"University of Minnesota","OTHER",{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":22,"phases":86,"briefSummary":88,"conditions":89,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":46},"100297734","the-effects-of-prophylactic-limited-palmar-fasciectomy-on-surgical-outcomes-and-scarring-100297734","NCT03155854","The Effects of Prophylactic Limited Palmar Fasciectomy on Surgical Outcomes and Scarring","The Effects of Prophylactic Limited Palmar Fasciectomy on Surgical Outcomes and Scarring for Dupuytren's Contracture Patients With Pretendinous Cord - Prospective Randomized Clinical Study (Pilot)","Inclusion Criteria:\n\n* Potential candidates for the study will be selected based upon clinical diagnosis of trigger finger with co-existing pretendinous cord. All potential subjects will have either failed non operative treatment or elected surgical treatment.\n\nExclusion Criteria:\n\n* \\\u003C18 years of age",{"count":55,"type":21},[87],"NA","Research is instrumental for improving medical care and the patient experience. Finding new surgical techniques can create better outcomes and minimize recovery time and complications for patients. Some patients undergoing trigger finger surgery with a pre-existing Dupuytren's cord may develop a thickened surgical scar after surgery, which can cause discomfort, difficulty with moving or using, and other complications in the affected finger(s) or hand. The investigator is investigating a surgical technique to minimize these potential complications and scarring after surgery.\n\nSubjects are being asked to take part in this research study because they have been diagnosed with trigger finger and pretendinous Dupuytren's cord and have decided to undergo surgery rather than try medical treatment.",[28],"2026-03-12",{"date":68,"type":38},{"date":93,"type":4},"2016-09",{"date":95,"type":21},"2026-12",{"name":97,"class":77},"Mayo Clinic",{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":105,"targetDuration":4,"studyType":22,"phases":107,"briefSummary":108,"conditions":109,"keywords":4,"overallStatus":118,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":46},"100610443","phase-2-nac-repair-for-post-surgical-pain-100610443","NCT07227649","NAC-REPAIR for Post-surgical Pain","NAC-REPAIR: N-Acetylcysteine-facilitated Redox-Immune Modulation for Post-surgical Analgesia and Injury Recovery","Inclusion Criteria:\n\n* Elective outpatient hand\u002Fupper-extremity or foot\u002Fankle surgery (single site; same-day discharge)\n* Baseline visit feasible ≤14 days pre-op\n* Can complete surveys\u002Fblood draw\n* Provides informed consent\n* Willing to follow dosing schedule and avoid restricted supplements\u002Fmeds\n\nExclusion Criteria:\n\n* Allergy to NAC\u002Fcapsule components □ NAC or high-dose antioxidants in past 14 days (unwilling to stop)\n* Chronic daily opioids ≥3 months or OUD\u002Fmaintenance therapy □ Pregnant\u002Fbreastfeeding or no contraception as applicable\n* Daily nitrates (nitroglycerin\u002Fisosorbide) □ Planned \\>24h admission, multistage\u002Ftrauma case □ Other interventional study within 30 days\n* Unable to swallow capsules \u002F malabsorption surgery affecting oral meds",{"count":106,"type":21},80,[25],"This pilot asks whether peri-operative N-acetylcysteine (NAC) improves recovery after common outpatient hand\u002Ffoot-ankle surgery-specifically, does NAC reduce pain and opioid use and enhance function by modulating redox-inflammatory pathways? Primary objectives are to establish feasibility (accrual, adherence, follow-up), estimate NAC vs placebo effects on pain, function, and opioid consumption, and characterize inflammatory signatures that may predict response.\n\nMethods: a single-site, double-blind, 1:1 randomized trial (N≈80) comparing NAC 1,200 mg twice daily for 14 days (starting pre-op) vs matching placebo; daily e-diaries for POD0-14; standardized outcomes (PROMIS Pain Interference; QuickDASH or FAAM; PGIC; opioid MME); and small blood draws pre-surgery and at two follow-up visits for cytokine profiling.",[110,111,112,113,28,114,115,116,117],"Carpal Tunnel Surgery","Trigger Finger Disorder","De Quervain Syndrome","Guyon's Canal","Morton Neuroma","Tarsal Tunnel Syndrome","Plantar Fasciopathy","Peroneal Nerve Entrapment","NOT_YET_RECRUITING","2025-11-12",{"date":121,"type":38},"2025-11-14",{"date":123,"type":21},"2026-01-15",{"date":125,"type":21},"2027-07-15",{"name":127,"class":77},"University of Arizona",{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":4,"eligibilityCriteria":134,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":135,"targetDuration":4,"studyType":22,"phases":137,"briefSummary":138,"conditions":139,"keywords":147,"overallStatus":118,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":46},"100605159","understanding-patient-preferences-when-deciding-on-a-voluntary-musculoskeletal-test-100605159","NCT07158892","Understanding Patient Preferences When Deciding on a Voluntary Musculoskeletal Test","Confirmation of Values and Preferences When Considering a Musculoskeletal Diagnostic Test: A Scenario-Based Study","Inclusion Criteria:\n\n* Adults (18+ years)\n* English literacy\n* Seeking musculoskeletal specialty care\n* Diagnosis of non-traumatic musculoskeletal condition (including but not limited to: carpal tunnel syndrome, lateral epicondylitis, osteoarthritis, trigger digit, Dupuytren's, De Quervain, or rotator cuff tendinopathy)\n\nExclusion Criteria:\n\n* Cognitive or physical impairment or severe psychiatric illness that would interfere with participation in the scenario-based discussion or completion of the survey instruments",{"count":136,"type":21},220,[87],"The goal of this clinical trial is to understand how people make decisions about imaging tests for common musculoskeletal problems (like arthritis, tendon problems, or nerve compression). The study involves adult patients attending a musculoskeletal specialty clinic.\n\nThe main questions it aims to answer are:\n\n1. Does having a structured conversation about the pros and cons of a test affect how much a person wants to have that test?\n2. Does that conversation help people feel more confident and less conflicted about their decision?\n\nResearchers will compare patients who have a values-based discussion with a researcher to those who receive brief written information about the test, to see if these approaches affect how people feel about having the test.\n\nParticipants will:\n\n* Read a brief scenario about a proposed diagnostic imaging test (like an X-ray, MRI, CT, or ultrasound).\n* Either take part in a short structured conversation or read brief information about the test.\n* Answer a short survey about their thoughts on the test.\n\nThis study does not involve actual medical testing or affect your clinical care. It is for research purposes only.",[140,141,142,143,144,28,145,146],"Non-traumatic Musculoskeletal Conditions","Carpal Tunnel Syndrome (CTS)","Lateral Epicondylitis","Osteoarthritis","Trigger Digit","Rotator Cuff Tendinopathy","De Quervain Disease",[148,149,150,151,152,153,154,155,156],"Musculoskeletal disorders","Diagnostic imaging","Shared decision making","Advance care planning (ACP)","Patient preferences","Health communication","Decision conflict","Scenario-Based Study","Orthopedic care","2025-09-02",{"date":159,"type":38},"2025-09-08",{"date":161,"type":21},"2025-09-10",{"date":163,"type":21},"2026-03-01",{"name":165,"class":77},"University of Texas at Austin",{"id":167,"slug":168,"hasResults":11,"nctId":169,"briefTitle":170,"officialTitle":171,"acronym":172,"eligibilityCriteria":173,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":174,"targetDuration":4,"studyType":22,"phases":176,"briefSummary":177,"conditions":178,"keywords":179,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":187,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":193,"locationsCount":46},"100576711","evaluating-ultrasound-guided-needle-knife-for-dupuytrens-contracture-100576711","NCT06788847","Evaluating Ultrasound-Guided Needle Knife for Dupuytren's Contracture","Advancing Dupuytren's Contracture Treatment: a Clinical Prospective Study on Ultrasound-Guided Needle Knife Dissection","DC-US","Inclusion Criteria:\n\n* Participants diagnosed with Dupuytren's Contracture.\n* Willing to undergo ultrasound-guided needle knife dissection\n\nExclusion Criteria:\n\n* Patients who have undergone previous surgery or needle apponeurotomy for Dupuytren's Contracture on the same hand.\n* Active hand infections, open wounds, or dermatological conditions in the treatment area.\n* Coagulopathy or use of anticoagulant that cannot be safely paused\n* Neuromuscular disorders affecting hand function\n* Pregnancy or breastfeeding\n* Uncontrolled systemic illnesses, such as poorly managed diabetes or cardiovascular disease.\n* Known hypersensitivity to local anesthetics.",{"count":175,"type":21},30,[87],"This study aims to evaluate the efficacy and safety of ultrasound-guided needle knife dissection in treating Dupuytren's contracture. The procedure is designed to improve hund function and minimize complications associated with the conventional surgical methods.",[28],[180,181,182,183,184,185],"Ultrasound-Guided Procedure","Dupuytrene's Contracture","Tubiana Grade","Fibrotic Cords Acupotomy","Functional Hand Recovery","Palmar Fascia Fibrosis","2025-01-23",{"date":188,"type":38},"2025-01-27",{"date":190,"type":38},"2025-01-19",{"date":192,"type":21},"2026-01-19",{"name":194,"class":77},"Mohamed Maher Ismail Ahmed Elashmawy",{"id":196,"slug":197,"hasResults":11,"nctId":198,"briefTitle":199,"officialTitle":200,"acronym":4,"eligibilityCriteria":201,"healthyVolunteers":202,"sex":16,"minAge":203,"maxAge":4,"enrollmentInfo":204,"targetDuration":4,"studyType":22,"phases":206,"briefSummary":207,"conditions":208,"keywords":209,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":212,"lastUpdatePostDateStruct":213,"startDateStruct":215,"completionDateStruct":217,"leadSponsor":219,"locationsCount":46},"100541490","radiation-therapy-for-dupuytrens-contracture-following-non-surgical-release-100541490","NCT06330545","Radiation Therapy for Dupuytren's Contracture Following Non-Surgical Release","A Prospective Clinical Trial of Radiation Therapy for Dupuytren's Contracture Following Surgical and Non-Surgical Release","Inclusion Criteria:\n\n* Age 45 or greater with DC\n* Extension deficit \\>10 degrees\n* Unable to simultaneously place the affected finger and palm flat on a table.\n* Women included in the study will be post-menopausal or using contraception, and a pregnancy test will be performed as standard of care.\n* For patients who are having multiple CCH injections, only the first 2 joints on given hand will be included\n\nExclusion Criteria:\n\n* Unsuccessful non-surgical release (\\> N\u002F1 disease)\n* They develop an open wound during CCH\n* Breast feeding or pregnancy\n* A chronic muscular, neurologic, or neuromuscular disorder affecting the hands.\n* Less than the age of 45\n* They have previously undergone radiation on the hand in which they plan to get CCH injections\n* They are pregnant women, impaired adults or prisoners",true,"45 Years",{"count":205,"type":21},95,[87],"The goal of this study is to learn about preventing recurrence of Dupuytren's Contracture. The main question it aims to answer are:\n\n• Does targeted radiation therapy decrease recurrence of Dupuytren's contracture after treatment with Collagenase Clostridium Histolyticum?\n\nParticipants will undergo:\n\n* Release of Dupuytren's Contracture after Collagenase Clostridium Histolyticum injection\n* Daily radiation therapy treatment for 5 days followed by 6-8 week rest period and then another course of 5 days of radiation therapy",[28],[210,211],"Dupuytren's contracture","radiation therapy","2024-11-20",{"date":214,"type":38},"2024-11-22",{"date":216,"type":38},"2024-09-16",{"date":218,"type":21},"2032-04",{"name":220,"class":77},"Dartmouth-Hitchcock Medical Center",{"id":222,"slug":223,"hasResults":11,"nctId":224,"briefTitle":225,"officialTitle":226,"acronym":4,"eligibilityCriteria":227,"healthyVolunteers":202,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":228,"targetDuration":4,"studyType":22,"phases":230,"briefSummary":231,"conditions":232,"keywords":233,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":237,"startDateStruct":239,"completionDateStruct":241,"leadSponsor":243,"locationsCount":245},"100462379","effectiveness-of-night-splinting-after-percutaneous-needle-fasciotomy-in-dupuytrens-contracture-100462379","NCT05300893","Effectiveness of Night Splinting After Percutaneous Needle Fasciotomy in Dupuytren's Contracture","Effectiveness of Night Splinting After Percutaneous Needle Fasciotomy in Dupuytren's Contracture - a Randomised Controlled Multicenter Trial","Inclusion Criteria:\n\n* 18 years of age and older,\n* Palpable Dupuytren strand with passive extension deficit according to stadium 1 and 2 of the classification of Tubiana in one or two fingers excluding the thumb, defined as at least 30 degrees in the MCP joint and\u002For at least 20 degrees in the PIP joint and a maximum of 75 degrees in the MCP or PIP joint\n\nExclusion Criteria:\n\n* Multiple, invasive or wide strands in the palm,\n* Skin irritation,\n* Strand localization in the digit only,\n* Digital nerve injury,\n* Any former treatment for Dupuytren's contracture in the same digit,\n* Thumb contracture,\n* Stadium 3 and 4 according to the classification of Tubiana",{"count":229,"type":21},154,[87],"Dupuytren's contracture (DC) is associated with progressive finger flexion and extension deficit caused by fibrosis in the palm and digits. Treatment options include minimally invasive procedures such as percutaneous needle fasciotomy (PNF) and collagenase clostridium histolyticum injections as well as open fasciectomy. PNF has recently become more popular in Sweden because it is an office-based procedure which is relatively easy to perform without the usual risks and costs of open surgery.\n\nAfter treatment with PNF patients usually continue with supervised rehabilitation, which includes physical therapy and night splinting. Whether night splinting is beneficial in terms of reducing recurrence of DC is currently debated.\n\nThis study aims to investigate whether night splinting after performed PNF helps to reduce recurrence rate or not. Patients who meet the inclusion criteria will be randomized into two groups: The first group will be treated as usual with physical therapy and night splinting after PNF. The second group will be treated with physical therapy without night splinting after PNF. Follow up includes physical examination regarding active range of motion, sensation and grip strength at procedure day and 2 weeks, 3, 12 and 36 months later as well as questionnaires regarding hand function, pain and quality of life at procedure day and 3, 12 and 36 months later. Patients who are randomized into the second group (no night splinting) will also be examined 3 weeks after PNF for observation in case of an early impairment regarding extension deficit.",[28,59],[234,235],"Percutaneous needle fasciotomy","Splint","2024-05-30",{"date":238,"type":38},"2024-05-31",{"date":240,"type":38},"2022-09-14",{"date":242,"type":21},"2027-01",{"name":244,"class":77},"Uppsala University",3,{"id":247,"slug":248,"hasResults":11,"nctId":249,"briefTitle":250,"officialTitle":251,"acronym":4,"eligibilityCriteria":252,"healthyVolunteers":11,"sex":16,"minAge":203,"maxAge":253,"enrollmentInfo":254,"targetDuration":4,"studyType":22,"phases":256,"briefSummary":258,"conditions":259,"keywords":270,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":273,"lastUpdatePostDateStruct":274,"startDateStruct":276,"completionDateStruct":278,"leadSponsor":280,"locationsCount":46},"100473080","phase-4-percutaneous-needle-fasciotomy---corticosteroid-injection-for-dupuytrens-contracture-100473080","NCT05440240","Percutaneous Needle Fasciotomy +\u002F- Corticosteroid Injection for Dupuytren's Contracture","Percutaneous Needle Fasciotomy (PNF) +\u002F- Corticosteroid Injection for Dupuytren's Contracture (DC) Affecting Metacarpophalangeal Joints (MCP) . A Randomized Controlled Trial","Sufficient correction of metacarpophalangeal (MCP) joint during the PNF treatment, defined as \\\u003C20° passive extension deficit (PED), is a prerequisite for inclusion.\n\nInclusion Criteria:\n\n* Dupuytren contracture (DC) of ≥ 20° PED in MCP joint measured with a goniometer\n* DC of either II-V finger\n* Well-defined\u002Fpalpable cord\n\nExclusion Criteria:\n\n* Legally incapacitated\n* Previous study inclusion with another finger ray\n* Isolated proximal interphalangeal (PIP) or distal interphalangeal (DIP) joint contracture, defined as MCP joint contracture \\\u003C 20° PED regardless of the deficit in the PIP or DIP joint\n* Previous hand surgery of the affected finger for any reason\n* Known allergy to the study medication\n* Anticoagulant therapy (Acetylsalicylic acid is NOT an exclusion criterion)\n* Pregnant or lactation\n* Insulin dependent diabetes mellitus\n* Ongoing systemic infection or local infection at the site of the procedure\n* Rheumatoid arthritis\n* Amyloidosis or mucopolysaccharidosis\n* Unable to communicate, cooperate or participate in follow-up","99 Years",{"count":255,"type":21},400,[257],"PHASE4","Comparing percutaneous needle fasciotomy +\u002F- corticosteroid injection for Dupuytren's contracture affecting metacarpophalangeal joints. A clinician-initiated, multicenter, randomized controlled trial.",[28,59,260,261,262,263,264,265,266,267,268,269],"Contracture","Joint Diseases","Musculoskeletal Diseases","Fibroma","Neoplasm, Fibrous Tissue","Neoplasms, Connective Tissue","Neoplasms, Connective and Soft Tissue","Neoplasms by Histologic Type","Neoplasms","Connective Tissue Diseases",[234,271,272],"Corticosteroid","Randomized controlled trial","2023-05-15",{"date":275,"type":38},"2023-05-17",{"date":277,"type":38},"2023-01-10",{"date":279,"type":21},"2030-03",{"name":281,"class":77},"Regionshospitalet Silkeborg"]